Ampiroxicam

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H21N3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0PV32JZB1J, chemically known as carbonic acid, ethyl 1-((2-methyl-3-((2-pyridinylamino)carbonyl)-2h-1,2-benzothiazin-4-yl)oxy)ethyl ester, s,s-dioxide but generally known as ampiroxicam, which bears US NIH Compound Identifier 2176. European Medicines Agency schedules Ampiroxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05488MIG. The term AMPIROXICAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). AMPIROXICAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ampiroxicam under HS 29349990 and SITC 51579. As of Q4 2014, AMPIROXICAM remains the US FDA Preferred Term for this commodity. Ampiroxicam bears US NLM identifiers UMLS ID C0246289 and NCI Concept Code C73073. SMILES: S1(=O)(=O)N(C(=C(OC(OC(=O)OCC)C)C2C1CCCC2)C(=O)NC1NCCCC1)C.